Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Precision Medicine and PET/Computed Tomography: Challenges and Implementation.

Literature DB >> 27863561

Precision Medicine and PET/Computed Tomography: Challenges and Implementation.

Abstract

Precision Medicine is about selecting the right therapy for the right patient, at the right time, specific to the molecular targets expressed by disease or tumors, in the context of patient's environment and lifestyle. Some of the challenges for delivery of precision medicine in oncology include biomarkers for patient selection for enrichment-precision diagnostics, mapping out tumor heterogeneity that contributes to therapy failures, and early therapy assessment to identify resistance to therapies. PET/computed tomography offers solutions in these important areas of challenges and facilitates implementation of precision medicine.

Entities: Chemical Disease Gene Species

Keywords: Biomarker; PET/computed tomography; Patient selection; Precision medicine

Mesh：

Year: 2016 PMID： 27863561 PMCID： PMC5134890 DOI： 10.1016/j.cpet.2016.08.010

Source DB: PubMed Journal: PET Clin ISSN： 1556-8598

21 in total

1. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Authors: Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares
Journal: Lancet Oncol Date: 2012-01-26 Impact factor: 41.316

2. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer.

Authors: Hannah M Linden; Svetlana A Stekhova; Jeanne M Link; Julie R Gralow; Robert B Livingston; Georgiana K Ellis; Philip H Petra; Lanell M Peterson; Erin K Schubert; Lisa K Dunnwald; Kenneth A Krohn; David A Mankoff
Journal: J Clin Oncol Date: 2006-05-08 Impact factor: 44.544

3. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

Authors: Bruce D Cheson; Richard I Fisher; Sally F Barrington; Franco Cavalli; Lawrence H Schwartz; Emanuele Zucca; T Andrew Lister
Journal: J Clin Oncol Date: 2014-09-20 Impact factor: 44.544

4. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer.

Authors: J E Mortimer; F Dehdashti; B A Siegel; K Trinkaus; J A Katzenellenbogen; M J Welch
Journal: J Clin Oncol Date: 2001-06-01 Impact factor: 44.544

5. Head and neck PET/CT: therapy response interpretation criteria (Hopkins Criteria)-interreader reliability, accuracy, and survival outcomes.

Authors: Charles Marcus; Anthony Ciarallo; Abdel K Tahari; Esther Mena; Wayne Koch; Richard L Wahl; Ana P Kiess; Hyunseok Kang; Rathan M Subramaniam
Journal: J Nucl Med Date: 2014-06-19 Impact factor: 10.057

6. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.

Authors: Tim P Hughes; Jaspal Kaeda; Susan Branford; Zbigniew Rudzki; Andreas Hochhaus; Martee L Hensley; Insa Gathmann; Ann E Bolton; Iris C van Hoomissen; John M Goldman; Jerald P Radich
Journal: N Engl J Med Date: 2003-10-09 Impact factor: 91.245

7. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.

Authors: J E Mortimer; F Dehdashti; B A Siegel; J A Katzenellenbogen; P Fracasso; M J Welch
Journal: Clin Cancer Res Date: 1996-06 Impact factor: 12.531

8. Fluorodeoxyglucose-positron-emission tomography imaging of head and neck squamous cell cancer.

Authors: R M Subramaniam; M Truong; P Peller; O Sakai; G Mercier
Journal: AJNR Am J Neuroradiol Date: 2009-11-12 Impact factor: 3.825

9. The preliminary study of 16α-[18F]fluoroestradiol PET/CT in assisting the individualized treatment decisions of breast cancer patients.

Authors: Yifei Sun; Zhongyi Yang; Yongping Zhang; Jing Xue; Mingwei Wang; Wei Shi; Beiling Zhu; Silong Hu; Zhifeng Yao; Herong Pan; Yingjian Zhang
Journal: PLoS One Date: 2015-01-24 Impact factor: 3.240

Review 10. The causes and consequences of genetic heterogeneity in cancer evolution.

Authors: Rebecca A Burrell; Nicholas McGranahan; Jiri Bartek; Charles Swanton
Journal: Nature Date: 2013-09-19 Impact factor: 49.962

2 in total

1. Evaluation of a High-Sensitivity Organ-Targeted PET Camera.

Authors: Justin Stiles; Brandon Baldassi; Oleksandr Bubon; Harutyun Poladyan; Vivianne Freitas; Anabel Scaranelo; Anna Marie Mulligan; Michael Waterston; Alla Reznik
Journal: Sensors (Basel) Date: 2022-06-21 Impact factor: 3.847

2. A Multi-parametric MRI-Based Radiomics Signature and a Practical ML Model for Stratifying Glioblastoma Patients Based on Survival Toward Precision Oncology.

Authors: Alexander F I Osman
Journal: Front Comput Neurosci Date: 2019-08-27 Impact factor: 2.380

2 in total